Neural Regeneration Research ›› 2026, Vol. 21 ›› Issue (7): 2526-2540.doi: 10.4103/NRR.NRR-D-24-01329

Previous Articles     Next Articles

Biomarker advancements in cerebral small vessel disease: An overview

Wenqian Luo, Chenhui Cao, Wenli Li, Ting Wei, Zeyu Zhao, Guanqing Wang, Xiaoli Li, Yanbin Li* , Bin Liu*   

  1. Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Institute of Neuroimmunology, Jinan, Shandong Province, China
  • Online:2026-07-15 Published:2025-10-16
  • Contact: Yanbin Li, MD, 13864006933@163.com; Bin Liu, MD, lbliubinlb@163.com.
  • Supported by:
    This work was supported by the Natural Science Foundation of Shandong Province, No. ZR2021MH043 (to BL).

Abstract: Cerebral small vessel disease is a condition caused by chronic cerebral hypoperfusion due to microvascular damage and is a major contributor to stroke and dementia. Traditionally, its diagnosis has relied primarily on neuroimaging findings. However, recent advances in the understanding of cerebral small vessel disease pathophysiology have opened new avenues for early detection and targeted therapeutic interventions. Notably, the identification and investigation of cerebral small vessel disease–related biomarkers have emerged as a promising strategy for early diagnosis. This review provides an overview of recent research on cerebral small vessel disease biomarkers, including plasma biomarkers, cerebrospinal fluid biomarkers, and genetic markers. Finally, we discuss future directions and trends in the clinical validation of these biomarkers.

Key words: aging, biomarkers, cerebral small vessel disease, cerebrospinal fluid, endothelial dysfunction, genes, inflammatory biomarkers, neurovascular unit